내용 바로 가기

낫적혈구병(Sickle Cell Disease)(소아청소년과)

빈혈 관리

Hydroxyurea with dose escalation for primary stroke risk reduction in children with sickle cell anaemia in Tanzania (SPHERE): an open-label, phase 2 trial. (새로운 창 열기)

Ambrose EE, Latham TS, Songoro P, Charles M, Lane AC, Stuber SE, Makubi AN, Ware RE, Smart LR

Source‎: Lancet Haematol. 2023 ;10(4):e261-71.

Indexed‎: PubMed 36870358

DOI‎: 10.1016/S2352-3026(22)00405-7

https://pubmed.ncbi.nlm.nih.gov/36870358/ (새로운 창 열기)

On the use of hydroxyurea/erythropoietin combination therapy for sickle cell disease. (새로운 창 열기)

el-Hazmi MA, al-Momen A, Kandaswamy S, Huraib S, Harakati M, al-Mohareb F, Warsy AS.

Source‎: Acta Haematol 1995;94(3):128-34.

Indexed‎: PubMed 7502628

https://www.ncbi.nlm.nih.gov/pubmed/7502628 (새로운 창 열기)

Combination erythropoietin-hydroxyurea therapy in sickle cell disease: experience from the National Institutes of Health and a literature review. (새로운 창 열기)

Little JA, McGowan VR, Kato GJ, Partovi KS, Feld JJ, Maric I, Martyr S, Taylor JG 6th, Machado RF, Heller T, Castro O, Gladwin MT.

Source‎: Haematologica 2006;91(8):1076-83.

Indexed‎: PubMed 16885048

https://www.ncbi.nlm.nih.gov/pubmed/16885048 (새로운 창 열기)

Use of erythropoietin in a pregnant Jehovah's Witness with sickle-cell disease. (새로운 창 열기)

Tan TL, Ahmad H, Jhavar R, Patel R, Harrison C, Oteng-Ntim E.

Source‎: J Obstet Gynaecol 2007;27(1):82-3.

Indexed‎: PubMed 17365469

DOI‎: 10.1080/01443610601062739

https://www.ncbi.nlm.nih.gov/pubmed/17365469 (새로운 창 열기)